Arterial Thrombosis Therapeutic Pipeline Review H1 2015 Research Report Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Arterial Thrombosis – Pipeline Review, H1 2015” report to its store. The report provides an overview of the Arterial Thrombosis’s therapeutic pipeline.

Arterial Thrombosis Therapeutic Pipeline Review

Arterial Thrombosis Therapeutic Pipeline Review

The report “Arterial Thrombosis – Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Arterial Thrombosis. Arterial thrombosis is a blood clot that develops in an artery. The two main causes of arterial thromboembolism are undoubtedly arteriosclerosis and atrial fibriallation. The risk of arterial thrombosis also increases with age, so older people are more commonly affected. Risk factors for arterial thrombosis includes smoking, fatness, high BP, increased levels of cholesterol, diabetes, older age, physical immobility and blood serum lipid abnormalities.

Complete report is available at http://www.rnrmarketresearch.com/arterial-thrombosis-pipeline-review-h1-2015-market-report.html.

The report also reviews key players involved in the therapeutic development for arterial thrombosis and special features on late-stage and discontinued projects. Companies discussed in this Arterial Thrombosis – Pipeline Review, H1 2015 report include Arena Pharmaceuticals, Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd. and Sanofi.

Drugs profile discussed in this report include AS-1468240, ASP-1645, ASP-6537, BAY-1213790, BMS-593214, C-3, E-5539, ER-410660, Ichorcumab, PZ-128, SAR-216471, Small Molecule to Inhibit Integrin alpha 2 beta 1 for Arterial Thrombosis, temanogrel hydrochloride and ticagrelor.

Order a Purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=314353. (This is a premium report priced at US$2000 for a single user License.)

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of content

List of Tables
Number of Products under Development for Arterial Thrombosis, H1 2015 8
Number of Products under Development for Arterial Thrombosis - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Arterial Thrombosis - Pipeline by Arena Pharmaceuticals, Inc., H1 2015 17
Arterial Thrombosis - Pipeline by Astellas Pharma Inc., H1 2015 18
Arterial Thrombosis - Pipeline by AstraZeneca PLC, H1 2015 19
Arterial Thrombosis - Pipeline by Bayer AG, H1 2015 20
Arterial Thrombosis - Pipeline by Bristol-Myers Squibb Company, H1 2015 21
Arterial Thrombosis - Pipeline by Eisai Co., Ltd., H1 2015 22
Arterial Thrombosis - Pipeline by Sanofi, H1 2015 23
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Mechanism of Action, H1 2015 28
Number of Products by Stage and Route of Administration, H1 2015 30
Number of Products by Stage and Molecule Type, H1 2015 32
Arterial Thrombosis Therapeutics - Recent Pipeline Updates, H1 2015 49
Arterial Thrombosis - Dormant Projects, H1 2015 54

List of Figures
Number of Products under Development for Arterial Thrombosis, H1 2015 8
Number of Products under Development for Arterial Thrombosis - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Products, H1 2015 14
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Top 10 Targets, H1 2015 25
Number of Products by Stage and Top 10 Targets, H1 2015 25
Number of Products by Top 10 Mechanism of Actions, H1 2015 27
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Top 10 Routes of Administration, H1 2015 29
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30
Number of Products by Top 10 Molecule Types, H1 2015 31
Number of Products by Stage and Top 10 Molecule Types, H1 2015 32

Explore more reports on Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics.

About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@RnRMR
since: 06/2012
Follow >
RnR Market Research
Like >
Follow us on
Visit website